REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 94 filers reported holding REATA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,129,458 | +1.3% | 30,693 | -9.7% | 0.00% | -20.0% |
Q1 2023 | $3,089,462 | +136.4% | 33,980 | -1.2% | 0.01% | +150.0% |
Q4 2022 | $1,306,780 | +53.0% | 34,398 | +1.2% | 0.00% | +100.0% |
Q3 2022 | $854,000 | -18.9% | 33,985 | -1.9% | 0.00% | -50.0% |
Q2 2022 | $1,053,000 | -7.1% | 34,648 | +0.2% | 0.00% | +100.0% |
Q1 2022 | $1,133,000 | +14.7% | 34,588 | -7.7% | 0.00% | 0.0% |
Q4 2021 | $988,000 | -73.2% | 37,468 | +2.2% | 0.00% | -80.0% |
Q3 2021 | $3,688,000 | -31.1% | 36,652 | -3.1% | 0.01% | -28.6% |
Q2 2021 | $5,355,000 | +15.0% | 37,837 | -19.0% | 0.01% | +16.7% |
Q1 2021 | $4,656,000 | -12.8% | 46,697 | +8.1% | 0.01% | -14.3% |
Q4 2020 | $5,339,000 | +29.6% | 43,187 | +2.1% | 0.01% | 0.0% |
Q3 2020 | $4,119,000 | -35.1% | 42,284 | +3.9% | 0.01% | -36.4% |
Q2 2020 | $6,351,000 | +27.8% | 40,707 | +18.2% | 0.01% | 0.0% |
Q1 2020 | $4,971,000 | -28.8% | 34,441 | +0.8% | 0.01% | -8.3% |
Q4 2019 | $6,983,000 | +178.1% | 34,160 | +9.2% | 0.01% | +140.0% |
Q3 2019 | $2,511,000 | -14.0% | 31,272 | +1.0% | 0.01% | -16.7% |
Q2 2019 | $2,920,000 | +18.1% | 30,950 | +7.0% | 0.01% | +20.0% |
Q1 2019 | $2,473,000 | +50.5% | 28,937 | -1.2% | 0.01% | +25.0% |
Q4 2018 | $1,643,000 | -29.8% | 29,294 | +2.4% | 0.00% | -20.0% |
Q3 2018 | $2,339,000 | +174.9% | 28,605 | +17.5% | 0.01% | +150.0% |
Q2 2018 | $851,000 | +137.0% | 24,336 | +39.1% | 0.00% | +100.0% |
Q1 2018 | $359,000 | -29.3% | 17,491 | -2.4% | 0.00% | 0.0% |
Q4 2017 | $508,000 | -10.9% | 17,925 | -2.2% | 0.00% | 0.0% |
Q3 2017 | $570,000 | +19.0% | 18,325 | +21.2% | 0.00% | 0.0% |
Q2 2017 | $479,000 | +68.7% | 15,125 | +20.8% | 0.00% | 0.0% |
Q1 2017 | $284,000 | +10.9% | 12,525 | +6.8% | 0.00% | 0.0% |
Q4 2016 | $256,000 | -19.2% | 11,725 | -2.5% | 0.00% | 0.0% |
Q3 2016 | $317,000 | +34.3% | 12,025 | +0.8% | 0.00% | 0.0% |
Q2 2016 | $236,000 | – | 11,925 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |